A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

A new study finds that GLP-1 medications are linked to lower overall cancer risk, particularly for endometrial and ovarian ...

The data, first presented at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting, showed that the phase 3 ...

Uterine cancer symptoms include irregular bleeding and pelvic pain, but early diagnosis through medical evaluation can lead ...

Investing.com -- PMV Pharmaceuticals Inc (NASDAQ:PMVP) stock rose 2.2% on Friday after the company reported encouraging clinical trial results for its cancer drug rezatapopt, showing responses across ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

After surviving three types of cancer and having to face the harsh realities of colorectal and endometrial cancer and basal ...

A common painkiller, ibuprofen, is showing surprising potential beyond easing aches. Research suggests it might help combat ...

Ibuprofen is a household name—the go-to remedy for everything from headaches to period pain. But recent research suggests ...

Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), ...

Step Pharma is financed to move its pipeline-in-a-product strategy forward on a broad front, after raising a €38 million (US$44.2 million) series C. That will see three ongoing trials testing the ...